达拉非尼治疗转移性非小细胞肺癌： 在BRAF V600E突变NSCLC患者中，达拉非尼联合曲美替尼的治疗方案能够显著延长患者的生存期，客观缓解率（ORR ...

引言结直肠癌（CRC）易发生肝转移，初始不可切除结直肠癌肝转移（CRLM）是临床处理中的难点。目前多项指南共识对 CRLM 的治疗做出推荐，同时临床研究结果的出炉也带来更多证据。2024 年 11 月，CAIRO5 研究事后分析结果公布[1]，为 ...

BRAF V600E mutations are common in different tumor types (more frequently in melanomas, colon and thyroid carcinomas). BRAF Alterations in Brain Tumors: Different Diagnostic Relevance of BRAF ...

非小细胞肺癌（NSCLC）是世界上最常见的恶性肿瘤之一。EGFR酪氨酸激酶抑制剂（EGFR-TKI）是表皮生长因子细胞受体突变（EGFR突变型）晚期NSCLC患者的首选一线治疗药物。不幸的是，药物耐药会不可避免地导致疾病进展。ALK和BRAF旁路信号 ...

用法及用量：推荐剂量为每日1次，每次2mg，饭前1小时或饭后2小时口服。 注册类别：化3+3 适应症：治疗不可切除或已经转移的BRAF V600E或V600K基因突变型黑色素瘤 产品特点及上市信息： 曲美替尼(trametinib)是GlaxoSmithKline开发的MEK抑制剂，制剂采用DMSO溶剂合物。

Novartis' two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for solid tumours that have a BRAF V600E mutation – regardless of where they occur in the body.

老规矩，奇点糕开头先问大家一个问题：在激活CD8+T细胞抗肿瘤免疫应答时，有哪些细胞会起到重要作用呢？回答树突状细胞（DCs）是肯定没问题的，它们的抗原呈递功能确实广为人知，但各位要记住了，从今天开始DCs可就不是问题唯一的“正解”了。因为在今天的《 ...

The small molecule PLX4032 (also RG7204), which Plexxikon is co-developing with Roche of Basel, specifically inhibits the V600E mutant BRAF, a constitutively active kinase present in more than ...

In combination with dabrafenib for the treatment of pediatric patients with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. <1yr or <8kg: not established.

Explore the challenges and advancements in anti-EGFR antibody treatment for metastatic colorectal cancer. Discover how ...

A live and archived webcast of the session will be accessible under “Events & Presentations” in the Investors section of Boundless Bio’s website and can be accessed via this link: About Boundless Bio ...